Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of adult AIDS clinical trials group protocol 370

AIDS

Volumn 14, Issue 11, 2000, Pages 1553-1561

  Kuritzkes, Daniel R ^a,k   Bassett, Roland L ^b   Johnson, Victoria A ^c,d   Marschner, Ian C ^b   Eron, Joseph J ^e   Sommadossi, Jean Pierre ^c   Acosta, Edward P ^c   Murphy, Robert L ^f   Fife, Kenneth ^g   Wood, Kenneth ^h   Bell, Dawn ⁱ   Martinez, Ana ^j   Pettinelli, Carla B ^l  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BIRMINGHAM VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g INDIANA UNIVERSITY   (United States)

^h FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁱ AIDS Clinical Trials Group Operations Center   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l NONE

more..

Author keywords

HIV 1; Non nucleoside reverse transcriptase inhibitor; Nucleoside analog; Protease inhibitor; Reverse transcriptase inhibitor

Indexed keywords

DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DELAVIRDINE; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 0033816183     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00011     Document Type: Article

References (28)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
2. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
3. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial. Italy, The Netherlands, Canada, and Australia study
4. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection
5. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter
6. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy
7. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
8. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
9. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial
10. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
11. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
12. In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome
13. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with HIV-1
14. Twice daily versus thrice daily indinavir (IDV) in combination with efavirenz (EFV): Surrogate marker responses and pharmacokinetics (PK)
15. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers
16. Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with Rescriptor (DLV) + Retrovir (ZDV) + Epivir (3TC)
17. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
18. Rapid quantification of indinavir in human plasma by high-performance liquid chromatography with ultraviolet detection
19. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
20. Antiretroviral therapy for HIV infection in 1997
21. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel
22. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
23. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease
24. Longer time to treatment failure and durability of response with efavirenz + ZDV + 3TC: First analysis of full 1266 patient cohort from study 006
25. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine
26. ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy
27. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261)
28. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed